Ask a room of women why they have not considered HRT and one answer dominates: breast cancer. That fear has a specific birthday. In July 2002, the Women's Health Initiative trial was stopped early and reported worldwide as proof that HRT causes breast cancer. Prescriptions halved in months and stayed low for twenty years.
The two decades since have been a slow, unglamorous correction. Not a vindication, and not a scandal confirmed: a correction, toward numbers that are smaller, more specific and more usable than the headlines in either direction. This guide lays those numbers out and lets you do the weighing, because that is the part nobody can do for you.
What 2002 actually found, and about whom
The WHI studied women aged 50 to 79, average age 63, mostly years past menopause, using the era's standard forms: oral estrogen from horse sources with a synthetic progestin. In the combined arm, breast cancer diagnoses were higher: roughly 4 extra cases per 1,000 women over five years.
Two findings never made the headlines. The estrogen-only arm, women who had a hysterectomy, showed no increase, and in long follow-up a slightly lower breast cancer rate. And the trial population, older and on older formulations, looked very little like a 51-year-old starting a transdermal estradiol patch with micronized progesterone today.
The size of the risk, in numbers you can hold
The honest modern summary for combined HRT: a small increase in breast cancer diagnoses, growing with duration of use, fading after stopping. In round terms, for women in their 50s over five years of use, the increase is in the region of a handful of extra cases per thousand women. Estrogen-only HRT shows little to no increase in most modern analyses.
Scale is everything here, so put it beside the risks nobody headlines. Drinking around two units of alcohol a day is associated with an increase of a similar order. Carrying significant extra weight after menopause is associated with a larger one. Regular exercise is associated with a reduction of about the same size in the other direction. HRT sits inside the band of ordinary lifestyle-sized risks, not outside it.
The kind of progesterone appears to matter too. The analyses that separate them suggest micronized progesterone, the body-identical capsule form now commonly prescribed, carries a lower breast risk than the older synthetic progestins that generated the 2002 data. The evidence is observational and still settling, but it runs consistently in that direction.
What moves the number for you specifically
A personal history of breast cancer changes this conversation completely: systemic HRT is generally avoided, and the alternatives conversation happens with your oncology team. A strong family history or a known gene variant means the decision belongs with a specialist, though even there the answer is individual assessment rather than automatic refusal.
Duration is a real variable: risk estimates grow with years of use, which is one reason for the annual review. Density of breast tissue, alcohol, weight and activity all sit in the same equation. The point of listing these is not alarm; it is that the number in the headlines is an average, and you are not an average.
How to hold it all
One framing serves this decision better than any statistic: both columns of the ledger are real. In one column, a small, duration-linked increase in breast cancer diagnoses with combined HRT. In the other, the most effective treatment known for flashes and sweats, solid protection for bone, and for many women the return of sleep and a workable brain.
Screening does not change the arithmetic but it changes the stakes: attending mammograms as invited matters slightly more on HRT, and telling the service you take it helps them read the image. Beyond that, the task is simply to weigh a small named risk against a concrete named benefit, in your own numbers, ideally with a clinician who deals in both. That is not what the 2002 headlines taught anyone to do. It is what the twenty years since have made possible.
Common questions
Does HRT cause breast cancer or promote it?
The distinction researchers draw is closer to promotion: hormone-sensitive cancers that exist can grow faster with hormones present, which shows up as more diagnoses during use and a fading of the excess after stopping. It is one reason the numbers, while real, are smaller than the word cancer makes them feel.
Is vaginal estrogen included in this risk?
No. Local vaginal estrogen reaches the bloodstream in tiny amounts, is not associated with the breast cancer signal, and is considered usable even in many situations where systemic HRT is not, sometimes including after breast cancer itself, with oncology input.
If I stop HRT, does the extra risk go away?
The excess declines after stopping and largely fades over the following few years in the major analyses. Duration of use is the variable that matters most, which is exactly what the yearly review is for.
Sources
- Women's Health Initiative, 2002 report and long-term follow-ups to 2020
- Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 2019
- British Menopause Society, HRT and breast cancer guidance
- The Menopause Society, 2022 hormone therapy position statement
- Cancer Research UK, lifestyle and breast cancer risk data
General information, not medical advice. Narrated never diagnoses.